Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361816870> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W4361816870 abstract "<div>Abstract<p><b>Purpose:</b> To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI).</p><p><b>Experimental Design:</b> Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clinical formulation of irinotecan were characterized. <i>In vivo</i> activity of irinotecan and nal-IRI was compared in xenograft models (3 each in nu/nu mice) of Ewing's sarcoma family of tumors (EFT), neuroblastoma (NB), and rhabdomyosarcoma (RMS). <i>SLFN11</i> expression was assessed by Affymetrix HuEx arrays, Taqman RT-PCR, and immunoblotting.</p><p><b>Results:</b> Plasma and tumor concentrations of irinotecan and SN-38 (active metabolite) were approximately 10-fold higher for nal-IRI than for irinotecan. Two doses of NAL-IRI (10 mg/kg/dose) achieved complete responses maintained for >100 days in 24 of 27 EFT-xenografted mice. Event-free survival for mice with RMS and NB was significantly shorter than for EFT. High <i>SLFN11</i> expression has been reported to correlate with sensitivity to DNA damaging agents; median <i>SLFN11</i> mRNA expression was >100-fold greater in both EFT cell lines and primary tumors compared with NB or RMS cell lines or primary tumors. Cytotoxicity of SN-38 inversely correlated with <i>SLFN11</i> mRNA expression in 20 EFT cell lines.</p><p><b>Conclusions:</b> In pediatric solid tumor xenografts, nal-IRI demonstrated higher systemic and tumor exposures to SN-38 and improved antitumor activity compared with the current clinical formulation of irinotecan. Clinical studies of nal-IRI in pediatric solid tumors (especially EFT) and correlative studies to determine if <i>SLFN11</i> expression can serve as a biomarker to predict nal-IRI clinical activity are warranted. <i>Clin Cancer Res; 21(5); 1139–50. ©2015 AACR</i>.</p></div>" @default.
- W4361816870 created "2023-04-05" @default.
- W4361816870 creator A5006269262 @default.
- W4361816870 creator A5008160506 @default.
- W4361816870 creator A5018464899 @default.
- W4361816870 creator A5020544186 @default.
- W4361816870 creator A5028983217 @default.
- W4361816870 creator A5035197780 @default.
- W4361816870 creator A5037677450 @default.
- W4361816870 creator A5040724883 @default.
- W4361816870 creator A5043205772 @default.
- W4361816870 creator A5054154479 @default.
- W4361816870 creator A5058354009 @default.
- W4361816870 creator A5065828728 @default.
- W4361816870 creator A5072369293 @default.
- W4361816870 creator A5084231089 @default.
- W4361816870 creator A5087913888 @default.
- W4361816870 date "2023-03-31" @default.
- W4361816870 modified "2023-09-25" @default.
- W4361816870 title "Data from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <i>SLFN11</i> Expression" @default.
- W4361816870 doi "https://doi.org/10.1158/1078-0432.c.6524660" @default.
- W4361816870 hasPublicationYear "2023" @default.
- W4361816870 type Work @default.
- W4361816870 citedByCount "0" @default.
- W4361816870 crossrefType "posted-content" @default.
- W4361816870 hasAuthorship W4361816870A5006269262 @default.
- W4361816870 hasAuthorship W4361816870A5008160506 @default.
- W4361816870 hasAuthorship W4361816870A5018464899 @default.
- W4361816870 hasAuthorship W4361816870A5020544186 @default.
- W4361816870 hasAuthorship W4361816870A5028983217 @default.
- W4361816870 hasAuthorship W4361816870A5035197780 @default.
- W4361816870 hasAuthorship W4361816870A5037677450 @default.
- W4361816870 hasAuthorship W4361816870A5040724883 @default.
- W4361816870 hasAuthorship W4361816870A5043205772 @default.
- W4361816870 hasAuthorship W4361816870A5054154479 @default.
- W4361816870 hasAuthorship W4361816870A5058354009 @default.
- W4361816870 hasAuthorship W4361816870A5065828728 @default.
- W4361816870 hasAuthorship W4361816870A5072369293 @default.
- W4361816870 hasAuthorship W4361816870A5084231089 @default.
- W4361816870 hasAuthorship W4361816870A5087913888 @default.
- W4361816870 hasConcept C112705442 @default.
- W4361816870 hasConcept C121608353 @default.
- W4361816870 hasConcept C126322002 @default.
- W4361816870 hasConcept C142724271 @default.
- W4361816870 hasConcept C150903083 @default.
- W4361816870 hasConcept C178790620 @default.
- W4361816870 hasConcept C185592680 @default.
- W4361816870 hasConcept C207001950 @default.
- W4361816870 hasConcept C2776715637 @default.
- W4361816870 hasConcept C2778256501 @default.
- W4361816870 hasConcept C2779682216 @default.
- W4361816870 hasConcept C2780259306 @default.
- W4361816870 hasConcept C2780844630 @default.
- W4361816870 hasConcept C502942594 @default.
- W4361816870 hasConcept C526805850 @default.
- W4361816870 hasConcept C54355233 @default.
- W4361816870 hasConcept C71924100 @default.
- W4361816870 hasConcept C81885089 @default.
- W4361816870 hasConcept C86803240 @default.
- W4361816870 hasConceptScore W4361816870C112705442 @default.
- W4361816870 hasConceptScore W4361816870C121608353 @default.
- W4361816870 hasConceptScore W4361816870C126322002 @default.
- W4361816870 hasConceptScore W4361816870C142724271 @default.
- W4361816870 hasConceptScore W4361816870C150903083 @default.
- W4361816870 hasConceptScore W4361816870C178790620 @default.
- W4361816870 hasConceptScore W4361816870C185592680 @default.
- W4361816870 hasConceptScore W4361816870C207001950 @default.
- W4361816870 hasConceptScore W4361816870C2776715637 @default.
- W4361816870 hasConceptScore W4361816870C2778256501 @default.
- W4361816870 hasConceptScore W4361816870C2779682216 @default.
- W4361816870 hasConceptScore W4361816870C2780259306 @default.
- W4361816870 hasConceptScore W4361816870C2780844630 @default.
- W4361816870 hasConceptScore W4361816870C502942594 @default.
- W4361816870 hasConceptScore W4361816870C526805850 @default.
- W4361816870 hasConceptScore W4361816870C54355233 @default.
- W4361816870 hasConceptScore W4361816870C71924100 @default.
- W4361816870 hasConceptScore W4361816870C81885089 @default.
- W4361816870 hasConceptScore W4361816870C86803240 @default.
- W4361816870 hasLocation W43618168701 @default.
- W4361816870 hasOpenAccess W4361816870 @default.
- W4361816870 hasPrimaryLocation W43618168701 @default.
- W4361816870 hasRelatedWork W1990414540 @default.
- W4361816870 hasRelatedWork W2007539997 @default.
- W4361816870 hasRelatedWork W2014811174 @default.
- W4361816870 hasRelatedWork W2030363482 @default.
- W4361816870 hasRelatedWork W2056165609 @default.
- W4361816870 hasRelatedWork W2069622785 @default.
- W4361816870 hasRelatedWork W2084081269 @default.
- W4361816870 hasRelatedWork W2124064787 @default.
- W4361816870 hasRelatedWork W2138805078 @default.
- W4361816870 hasRelatedWork W2257891551 @default.
- W4361816870 isParatext "false" @default.
- W4361816870 isRetracted "false" @default.
- W4361816870 workType "article" @default.